9.96
+0.295(+3.05%)
Currency In USD
Address
240 East Grand Avenue
South San Francisco, CA 94080
United States of America
Phone
650 388 5600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
122
First IPO Date
April 24, 2020
| Name | Title | Pay | Year Born |
| Dr. Jacob M. Chacko M.B.A., M.D. | President, Chief Executive Officer & Director | 1.04M | 1979 |
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | 100,000 | 1957 |
| Mr. Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer | 684,155 | 1975 |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer | 735,587 | 1967 |
| Dr. Edna Chow Maneval Ph.D. | Executive Vice President of Clinical Development | 0 | 1961 |
| Dr. Charles L. Sawyers B.A., M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | 0 | 1959 |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | General Counsel | 0 | 1973 |
| Dr. Scott W. Lowe Ph.D. | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer | 0 | 1964 |
| Mr. Daniel Iazzetti | Vice President & Head of People | 0 | N/A |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
